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Clinical practice guidelines convey evidence-based advice 
for the management of specific diseases or conditions. While 
recommendations in guidelines are adapted by clinicians to 
best serve individual patients, guidelines are also a tool for 
improving population health and broadly elevating the stand-
ard of care [1, 2] across a country or region. Indeed, some 
guidelines are even international in scope. The purpose of 
this review is to consider the particular benefits and limita-
tions of international clinical practice guidelines. In addi-
tion, we consider the feasibility and utility of alternative 
forms of international collaboration among physicians that 
also lead to consensus documents regarding patient care.
Benefits of international guidelines
The most obvious advantage of international clinical prac-
tice guidelines is that they avoid duplication of effort. One 
set of guidelines applicable to all are efficient and relatively 
inexpensive to produce, and easy to disseminate widely. 
Such guidelines also minimize confusion among guide-
lines users, who do not have to select the most appropriate 
guidelines from a menu of documents addressing the same 
issue. At a content level, international guidelines may bring 
together evidence and wisdom from many quarters, culmi-
nating in balanced and comprehensive recommendations 
that are founded on a breadth of salient information that 
was surfaced during the guidelines development process.
Challenges and limitations of international 
guidelines
Challenges inherent in the construction of international 
guidelines can slow and prevent their development. To begin 
with, standards of care frequently differ across countries and 
regions. Patient and provider expectations of appropriate 
care may also differ, with the latter influenced by variation 
in medical training in different areas. In particular, access to 
resources and therapies may be greater in wealthier countries 
than in those with widespread poverty or a two-tiered health 
care system. Residents of countries with single-payer health 
care systems may accept a greater degree of uniformity in 
clinical guidelines than those living in systems that are more 
fragmented and allow for greater individual variation in care 
approaches. Regulatory agencies that review new drugs or 
devices usually have a national or regional mandate, and 
medical products available in one country may still be await-
ing testing or approval in another. Costs of therapies may 
also differ, so even approved treatments may be out of reach 
for most, and hence not first-line treatments, in some areas.
The risk of failure to reach consensus on international 
guidelines due to variations in local or regional standards 
of care is not theoretical, but in fact fairly common. For 
instance, development of cross-national and international 
guidelines for treatment of nonmelanoma skin cancers such 
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as basal cell carcinoma is inhibited by the differential availa-
bility of complex surgical therapies, like Mohs micrographic 
surgery. Reduced availability and limited resources to pay 
for such therapies in certain countries leads to local stand-
ards of care that are more tilted toward destructive and topi-
cal treatments, or simple excision. Another instance of lack 
of international consensus occurred during a recent effort to 
develop guidelines for chronic hand eczema [3].
Given the many causes for variation in care delivery across 
countries, any international guidelines that are produced may 
need to be excessively vague, or circumscribed by exceptions 
and special considerations. This degree of complexity may 
impede the readability and usability of these guidelines.
Best practices in the development 
of international guidelines
Before starting work on international guidelines for a disease 
or condition, a feasibility assessment may be appropriate. 
Team members may thereby determine which countries or 
regions have sufficiently similar political and healthcare sys-
tems, patient and provider expectations, and national wealth 
to be part of the project. The scope of the guidelines may 
need to be well-defined, and potentially restricted, to mini-
mize the need for exceptions for certain countries or regions. 
Some especially contentious treatment-related questions may 
be deferred, or left to the judgment of the individual practi-
tioner. International guidelines may be most appropriate for 
very rare conditions or diseases, for which little is known and 
individual country-specific guidelines are impractical [4, 5].
While members of the guidelines group will not only be 
technical experts, but also collegial partners who work to 
resolve disagreements, constructive compromise will at times 
be elusive. A formal dispute resolution mechanism may there-
fore be helpful. Additionally, legal documents, such as memo-
randa of understanding may clarify each constituent group’s 
right and responsibilities, including the conditions under 
which they may withdraw from the guidelines process. Des-
ignating co-chairs of the workgroup to represent each country 
or region can be an effective informal approach to increase 
solidarity and preempt excessive conflict. During executive 
sessions, co-chairs may come up with possible solutions that 
are later presented to the entire group for approval.
Alternatives to international guidelines
If international clinical practice guidelines are not feasible, 
other international collaborations can be convened to stand-
ardize and elevate care delivery worldwide. The purpose of 
such collaborations is to come together to promulgate rules 
and recommendations that are less subject to regional vari-
ation or local norms.
Working groups on nomenclature, definitions, 
diagnostic criteria, and measurement
For some diseases and conditions, nosology and nomencla-
ture remain unsettled. For newly recognized conditions, even 
basic definitions, and the features that are always or some-
times present, may need to be clarified. Working groups can 
be assembled with members from many countries to bet-
ter understand disease categories, and boundaries between 
types. Clinical manifestations of disease, classification 
and staging, or levels of severity, may need to be updated 
[6]. Examples of such collaborations abound, and can be 
regional or worldwide, and focused on one or a few diseases, 
or many. For instance, the International Statistical Classifi-
cation of Diseases and Related Health Problems (ICD) is a 
classification list developed for international use under the 
auspices of the World Health Organization (WHO), and is 
currently on its 11th iteration [7]. So-called core outcome 
sets (COS), [8–12] minimum sets of outcomes to be included 
in clinical studies of a disease of condition, are developed 
and validated using diverse, international working groups 
that themselves loosely follow rules by other international 
groups [10, 13].
Preclinical consensus on etiology and pathogenesis 
of disease, or mechanism of action of diagnostic 
or therapeutic interventions
Potential cross-border collaborations can aim to clarify the 
pathogenesis of disease or mechanism of action of drugs, 
devices, and other therapies. Knowledge gained can facilitate 
drug discovery, or help redeploy existing therapies for new 
indications. During crises, including pandemics and other 
global emergencies that introduce new threats to patients, 
such collaborations can speed the dissemination of knowl-
edge so that new findings can immediately be applied to 
patient care.
Safety guidance pertaining to novel therapeutics
New therapies may alleviate patient suffering, but they may 
also be associated with undetected adverse events. Phase 3 
clinical testing leading to regulatory approval may be insuf-
ficient to detect uncommon and rare adverse events, which 
are only evident once a therapy is marketed and widely used. 
Pooling clinical experience, including safety information, 
across countries or regions can increase the ability to detect 
and quantify such risks [14]. Countries in which approvals 
have not yet been obtained may benefit from foreknowledge 
of safety limitations, labeling and indications may be suit-
ably altered, and preventable morbidity and mortality may 
thus be avoided.
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Planning of future clinical research
Clinical research can be time-consuming and resource-inten-
sive. Ideally, the most important clinical quandaries should be 
investigated with well-designed, adequately powered studies 
that can resolve the question. International collaborations may 
be assembled to refine and delineate important questions, and 
design appropriate clinical trials. In addition, centers around 
the world may participate in enrolling patients, even if local 
IRBs retain their purview to oversee safety. Large, interna-
tional trials, while difficult to manage, can be highly powered 
and produce results that are generalizable to many popula-
tions, including different ethnicities [15]. For rare or uncom-
mon diseases or conditions, international recruitment may be 
necessary to find enough willing participants.
Summary
In conclusion, there are several approaches to harnessing 
the diversity and depth of knowledge from many countries 
to improve patient care. Under certain circumstances, such 
as when there is limited variation in resource availability 
and the standard of care, development of a complete set 
of international clinical practice guidelines may be feasi-
ble. Otherwise, international collaborations may be more 
focused, restricted to developing consensus on issues such 
as nomenclature, diagnostic criteria, pathogenesis of dis-
ease, outcomes measurement, safety of therapies, and needs 
assessment.
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